CARDIAC INVOLVEMENT IN HEMOLYTIC DISEASES

View at publisher Summarise with VIRAT
Authors: Oğuzhan Kayar
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Hemolytic anemia develops when the shortened lifespan of erythrocytes results in an uncompensated loss despite increased erythropoiesis in the bone marrow. Hemolysis can occur intravascularly or extravascularly, immune or non-immune involvement, depending on intracorpuscular and extracorpuscular factors. Hemoglobinopathies, defects in erythrocyte membrane proteins, and deficiencies in enzymes critical for erythrocyte metabolism result in hemolytic anemia due to the premature destruction of erythrocytes, either congenitally or acquired. As a result of the increased life expectancy of individuals with hemolytic disease, the incidence of cardiovascular related morbidity and mortality has increased. Hemolytic diseases have a multifaceted effect on the cardiovascular system through chronic anemia, hemolysis related endothelial dysfunction, and transfusion related iron overload. Acute hemolytic conditions are compensated for by tachycardia and increased cardiac output. Heart failure, ventricular dilatation, cardiomyopathy and volume overload that develop as a result of the prolonged process are significant cardiovascular complications. During the process of removing free hemoglobin released into the blood as a result of hemolysis, the decrease in nitric oxide in the blood contributes to vascular endothelial dysfunction. This is a risk factor for the development of pulmonary arterial hypertension. Chronic hemolysis and excessive blood transfusions can cause severe iron overload, which can affect the heart and conduction system, causing heart failure, cardiomyopathy, and arrhythmias. Clinical signs of cardiac dysfunction due to iron overload usually appear several years after iron begins to accumulate in the heart. Therefore, measuring the iron load in the heart is critical for early diagnosis. Knowledge of appropriate cardiac approaches plays an important role in the early diagnosis and treatment of patients. Starting iron chelation therapy early, before cardiac symptoms appear, and carefully managing diuresis and effectively controlling hypotension when heart failure develops can significantly reduce mortality. Early and regular screening using non invasive methods in children with hemolytic disease can improve quality of life. Echocardiography should be routinely performed to measure cardiac function and estimated pulmonary artery pressure, and cardiac MR-T2* should be routinely used to measure iron load in patients with high transfusion burden. This may reduce the incidence of cardiac events during the transition to adulthood. This section comprehensively addresses cardiac involvement in hemolytic anemias, including pathophysiological mechanisms, clinical presentation, and follow-up strategiesKeywords: Anemia; Hemolysis; Thalassemia; Hemoglobin; Iron overload; Heart failure

Fields of Study & Subjects

Hemoglobinopathies and Related Disorders Erythrocyte Function and Pathophysiology Blood groups and transfusion

Publication details

Journal / source
Turkiye Klinikleri eBooks
Pages
327–337
Publication date
1 January 2026
Language
EN
Document type
Book chapter